About

PhoreMost is unlocking the full potential of TPD through its proprietary target identification platforms, SITESEEKER® and GlueSEEKER®, pioneering the use of mini-protein engineering to develop novel therapeutic strategies.

Targeted Protein Degradation (TPD) is a promising approach to eliminating toxic or disease-associated proteins from cells, offering a powerful strategy to address previously undruggable targets. Despite the existence of over 600 known E3 ligases, the pharmaceutical industry remains largely dependent on a limited set—such as Cereblon—for degrader-based drug development.

The company has advanced several next-generation ligase programmes through proof-of-concept and is progressing multiple degrader assets toward preclinical studies. PhoreMost has also established a number of strategic partnerships, including disclosed alliances with Roche, Boehringer Ingelheim, and Sentinel Oncology.